Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

• First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability
• KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF)
• KIT2014’s unique mode of action improves respiratory symptoms
  by promoting bronchodilation and reducing lung inflammation

 

Turin, Italy – 19 June 2026 – Kither Biotech Pty Ltd and Kither Biotech srl, a clinical-stage biopharmaceutical group of companies developing innovative therapies for respiratory diseases, today announced the successful completion of their Phase 1 clinical study of KIT2014 in healthy participants.